NGL Fine-Chem Limited

NSE NGLFINE.NS

NGL Fine-Chem Limited EBIT Margin for the year ending March 31, 2024: 16.60%

NGL Fine-Chem Limited EBIT Margin is 16.60% for the year ending March 31, 2024, a 58.12% change year over year. EBIT ratio is the ratio of EBIT to revenue, measuring a company's operating profitability without considering non-operating income or expenses.

NGL Fine-Chem Limited EBIT Margin for the year ending March 31, 2023 was 10.50%, a -52.06% change year over year.
NGL Fine-Chem Limited EBIT Margin for the year ending March 31, 2022 was 21.90%, a -30.01% change year over year.
NGL Fine-Chem Limited EBIT Margin for the year ending March 31, 2021 was 31.29%, a 217.12% change year over year.
NGL Fine-Chem Limited EBIT Margin for the year ending March 31, 2020 was 9.87%, a -50.16% change year over year.

Key data

Date	EBIT Margin	EPS (Basic)	EPS (Diluted)	Shares (Basic, Weighted)

NSE: NGLFINE.NS

NGL Fine-Chem Limited

CEO	Mr. Rahul Jayant Nachane
IPO Date	July 8, 2022
Location	India
Headquarters	301, E Square
Employees	682
Sector	Healthcare
Industries Pharmaceuticals Chemicals & Advanced Materials Cleaning Supplies Cosmetics Drugstores & Retail Pharmacies Personal Care Pet Food Plastics

Description

NGL Fine-Chem Limited manufactures and sells pharmaceuticals and intermediates for use in veterinary and human health worldwide. It offers active pharmaceutical ingredients, such as diminazene aceturate, diminazene diaceturate, homidium chloride, nitroxynil, clorsulon, parvaquone, buparvaquone, isometamidium chloride hydrochloride, toldimfos sodium, butaphosphan, imidocarb dipropionate, triclabendazole, ractopamine HCl, S-methoprene, praziquantel, toltrazuril, decoquinate, flunixin meglumine, carprofen, fenbendazole, amitraz, and marbofloxacin for animal health applications; and nitazoxanide, atovaquone, and ranolazine for human health applications. The company also provides various intermediate products; and finished dosage forms in granules and tablets. NGL Fine-Chem Limited was incorporated in 1981 and is based in Mumbai, India.

Key trends

Past 5 years